From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis
Therapeutic Advances in Musculoskeletal Disease · 2025-08 · 17
DOI: 10.1177/1759720x251398430 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Musculoskeletal Disease, online erschienen am 17.12.2025. Verfasst von Iván Arias-de la Rosa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba/R…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, and by the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III, junta de andalucía.
Abstract (Originalsprache)
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by a complex interplay of molecular factors. Despite advances in understanding its pathophysiology, diagnostic delays and the absence of personalized treatment strategies remain significant challenges. This review provides a comprehensive analysis of imaging techniques and molecular approaches to improve disease characterization. Advanced imaging methods, including magnetic resonance imaging, positron emission tomography, and artificial intelligence (AI)-driven models, have enhanced diagnostic accuracy, reduced variability in interpretation, and facilitated early disease detection. In parallel, omics technologies have provided valuable insights into disease pathogenesis. Genomic studies have identified susceptibility loci beyond human leukocyte antigen B27, implicating key immune pathways such as interleukin-23/interleukin-17 signaling. Epigenomic modifications, particularly DNA methylation, play a key role in regulating gene expression in immune cells, especially within genetically predisposed loci. Transcriptomic studies have uncovered dysregulated immune pathways and revealed novel cellular players in disease pathogenesis, including CD99 + neutrophils, natural killer cells, and microRNAs—important post-transcriptional regulators that have shown high diagnostic accuracy when assessed in peripheral blood mononuclear cells. Proteomic analyses have further contributed by identifying potential biomarkers and therapeutic targets in blood using advanced technologies, highlighting molecules such as tumor necrosis factor, FK506-binding protein-like (FKBPL), mitogen-activated protein kinase 14 (MAPK14), interleukin 7 receptor, and interleukin-23 receptor, among others. Future research should focus on combining multi-omics data with AI-driven approaches to improve biomarker discovery, optimize patient classification, and guide personalized treatments. Bridging the gap between molecular insights and clinical applications will enable precision medicine strategies, improving early diagnosis and therapeutic outcomes in axSpA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba/Reina Sofia University Hospital, GC-05 Group, Second Floor, IMIBIC, Avd…
- Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain.
- Instituto de Investigación Sanitaria de Castilla-La Mancha, Toledo, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Toledo, Spain.
- Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba/Reina Sofia University Hospital, Córdoba, Spain.
- Cobiomic Bioscience SL, Córdoba, Spain.
ORCID-Profile: Iván Arias-de la Rosa, Clementina López-Medina C, Nuria Barbarroja, María Ángeles Puche-Larrubia
Förderung
- European Union, and by the Spanish Ministry of Science, Innovation and Universities
- Instituto de Salud Carlos III
- junta de andalucía
Zitieren
APA
Arias-de la Rosa, I., Martín-Salazar, J. E., Cuesta-López, L., López-Medina C, C., Escudero-Contreras, A., Collantes-Estévez, E., Barbarroja, N., & Puche-Larrubia, M. Á. (2025). From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 17. https://doi.org/10.1177/1759720x251398430
Vancouver
Arias-de la Rosa I, Martín-Salazar JE, Cuesta-López L, López-Medina C C, Escudero-Contreras A, Collantes-Estévez E, et al. From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease. 2025;17. doi:10.1177/1759720x251398430
BibTeX
@article{AriasdelaRosa2025,
author = {Arias-de la Rosa, Iván and Martín-Salazar, Jesús Eduardo and Cuesta-López, Laura and López-Medina C, Clementina and Escudero-Contreras, Alejandro and Collantes-Estévez, Eduardo and Barbarroja, Nuria and Puche-Larrubia, María Ángeles},
title = {From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis},
journal = {Therapeutic Advances in Musculoskeletal Disease},
year = {2025},
volume = {17},
doi = {10.1177/1759720x251398430}
}
EUVIMED